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Abstract
Background Bile salts likely contribute to liver injury in
patients with primary sclerosing cholangitis (PSC) and
primary biliary cholangitis (PBC). Fibroblast growth factor
19 (FGF19) is a bile salt-induced enterokine with hepato-
protective potential as it suppresses de novo bile salt syn-
thesis. Here, we evaluated the bile salt receptor FXR/
FGF19 gut–liver axis in PSC and PBC patients.
Methods Fasted patients with PSC (n = 12) and PBC
(n = 10), and healthy controls (HC; n = 10) were orally
challenged with the natural FXR agonist chenodeoxycholic
acid (CDCA 15 mg/kg). Blood was sampled hourly until
8 h afterwards. Serum FGF19 and bile salt excursions were
determined. Serum levels of 7a-hydroxy-4-cholesten-3-one
(C4), reflecting bile salt synthesis, were measured as a
biomarker of FGF19 response.
Results Baseline serum FGF19 levels were comparable
between groups, while fasted bile salt levels in PSC
patients were elevated. Upon CDCA challenge, HC and
PBC patients showed a serum FGF19 peak after 4 h fol-
lowed by a decline. PSC patients showed a prolonged and
elevated serum FGF19 response up to 8 h, combined with a
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sustained serum elevation of CDCA and other bile salts. In
general, C4 levels declined following FGF19 elevation. In
PSC patients with less favorable prognosis, baseline C4
levels were drastically suppressed and did not further
decline.
Conclusion Following an oral CDCA challenge, PSC
patients showed an impaired clearance of CDCA and a
prolonged serum FGF19 response. FXR agonist therapy in
PSC could cause prolonged exposure to elevated levels of
FGF19, and we propose careful monitoring for detrimental
side effects in patient studies.
Keywords Primary sclerosing cholangitis 
Chenodeoxycholic acid  Fibroblast growth factor 19 
Farnesoid X receptor
Introduction
Primary sclerosing cholangitis (PSC) is in its classical form
a chronic cholestatic liver disease characterized by fibrotic
strictures and saccular dilatations of the intra- and extra-
hepatic bile ducts [1]. Destruction and obliteration of
medium- and large-sized bile ducts leads to bile retention,
chronic cholestasis and biliary cirrhosis. The initial lesions
in PSC are thought to be the consequence of a disturbed
immunological response, with a possible role for bile or
bile salts in perpetuating the disease [2].
Bile salt homeostasis in the liver is tightly regulated.
Recent studies have indicated that bile salt synthesis in the
liver is controlled by fibroblast growth factor 19 (FGF19)
produced in the terminal ileum [3]. FGF19 is produced in
ileocytes upon activation of the farnesoid X receptor (FXR)
by bile salts absorbed from the intestinal lumen. Among
the various bile salts, chenodeoxycholic acid (CDCA) is
the most potent natural FXR-agonist [4]. Upon release into
the portal circulation, FGF19 binds to FGFR4 at the sinu-
soidal membrane of hepatocytes. This leads to activation of
MAP kinases and transcriptional repression of CYP7A1,
encoding the rate-limiting enzyme in bile salt synthesis.
In vivo, this repression can be followed by measuring
serum levels of the bile salt intermediate 7a-hydroxy-4-
cholesten-3-one (C4) [5]. By reducing bile salt synthesis,
FGF19 has a hepatoprotective effect. A possible downside
of FGF19 is its presumed tumorigenicity [6–8]. Prolonged
exposure to high levels of FGF19 could contribute to the
enhanced risk for bile duct, gallbladder and colon cancer in
PSC [9–11].
The majority of patients with PSC have concomitant
inflammatory bowel disease (IBD) and one may question
if, in that setting, proper control of bile salt synthesis by the
FXR/FGF19 axis is maintained. The objective of the
present study was to evaluate this gut–liver signaling axis
in patients with chronic cholestatic liver disease.
Materials and methods
Study subjects, oral CDCA challenge and blood
sampling
Patients with PSC (n = 12) and primary biliary cholangitis
(PBC, n = 10) were recruited from the outpatient hepa-
tology clinic at the Academic Medical Center in Amster-
dam. Healthy controls (HC, n = 10), matched for gender
and age with the PSC patients, were approached via a
written announcement.
The Mayo Risk Score (MRS) for PSC, a prognostic
model used to estimate event-free survival and classified as
low (MRS B 0), intermediate (0\MRS B 2) or high
(MRS[ 2) risk, was calculated [12]. For the present study,
MRS was re-categorized as low (MRSlow; MRS B 0,
n = 7) and intermediate to high MRS (MRSintermediate-high;
MRS[ 0, n = 5).
The Mayo Risk Score (MRS) also has prognostic value
for estimating event-free survival in PBC, and is classified
as low (MRS B 3.5), intermediate (3.5\MRS B 3.9) or
high (MRS[ 4) risk [13]. Note that calculation of MRS
for PBC employs different parameters, yielding values that
do not allow direct comparison with MRS for PSC.
PBC patients and those PSC patients taking
ursodeoxycholic acid (UDCA) were asked to suspend
UDCA use during 1 week before the start of the study.
Following overnight fasting, all study subjects were orally
administered chenodeoxycholic acid (CDCA; Sigma-Tau
Arzneimittel, Dusseldorf, Germany) at a dose of 15 mg/kg
body weight (total number of ingested 250 mg capsules
was rounded downwards), based on a previous report of
succesful pharmacologic activitation of FXR in human
subjects [14].
Blood samples were obtained from an indwelling can-
nula placed in a cubital vein at baseline and at hourly
intervals for up to 8 h after CDCA intake. During this
sampling period, all participants refrained from food but
had free access to water.
Blood chemistry
Following collection of blood, serum was prepared and
stored at -80 C until analysis of FGF19, total bile salts,
and 7a-hydroxy-4-cholesten-3-one (C4) levels at all sam-
pling points. Alanine aminotransferase (ALT), gamma-
glutamyltransferase (GGT) and alkaline phosphatase
(ALP) were determined at baseline, 4 and 8 h after CDCA
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intake, using a Cobas Modular Analyzer (Roche Diagnos-
tics, Germany).
FGF19 levels were determined by ELISA as previously
described [15]. Total bile salt (TBS) levels were deter-
mined by an enzymatic cycling assay (Diazyme, Poway,
CA, USA). Serum levels of C4 were determined by LC–
MS as described in detail in the Supplemental Data. Serum
bile salt composition was determined in samples collected
at baseline and additional time points of interest, as
described elsewhere [16].
Statistical analysis
Differences between HC, PSC and PBC patient groups at
baseline were evaluated using (non-)parametric ANOVA
and post hoc tests with Bonferroni–Holm correction for
multiple testing. Repeated measurement ANOVA was used
to evaluate the response to CDCA in the respective study
groups. In case of ALT, a non-parametric Friedman test for
repeated measures was performed for each (sub)group.
AUC0-8h was calculated as net change from baseline using
the trapezoid method. Statistical analyses were performed
using SPSS v.20, and statistical significance was accepted
at p\ 0.05. Data in graphs are shown as median and
interquartile range unless indicated otherwise, whereas data
in tables are shown as median (range).
Results
Patient groups
Patient characteristics and liver biochemistry are shown in
Table 1. In the PSC group, seven patients had a low MRS
(MRSlow), two patients had an intermediate MRS and three
patients had a high MRS (grouped together as MRSinter-
mediate-high). In the PBC group, three patients had a low
MRS, two patients had an intermediate MRS and five
patients had a high MRS. None of the study subjects had a
history of bowel surgery. Of PSC patients, six had ulcer-
ative colitis and two had Crohn’s disease, with a single
patient per IBD subtype having mild terminal ileitis at the
time of the study. UDCA was used by ten PSC patients
(83 %), of which four temporarily discontinued its use. All
PBC patients used UDCA, with a single patient refraining
from discontinuation. The oral administration of CDCA
with a median bolus of 1250 mg did not lead to side effects
or complications in any of the subjects.
Serum bile salt levels and composition at baseline
Total bile salt (TBS) levels at baseline were higher in the
PSC than in the HC and PBC groups (Table 2; Fig. 1a). In
PSC patients, TBS levels at baseline were considerably




n 10 10 12 7 5
Male [n (%)] 5 (50) 0 (0) 7 (58) 3 (43) 4 (80)
Age (years) [median (range)] 51
(27–73)
63 (43–78) 48 (30–70) 46 (30–70) 50 (35–70)
Large duct PSC [n (%)] N.A. N.A. 12 (100) 7 (100) 5 (100)
Disease duration (years) [median (range)] N.A. 10 (1–35) 11 (4–24) 7 (4–12) 17 (4–24)
Ulcerative colitis [n (%)] 0 (0) 0 (0) 6 (50) 3 (43) 3 (60)
Crohn’s disease [n (%)] 0 (0) 0 (0) 2 (17) 2 (29) 0 (0)
Ursodeoxycholic acid use [n (%)] N.A. 10 (100) 10 (83) 6 (86) 4 (80)
AST (U/L) [median (range)] (N:\ 40 U/L) N.D. 29 (17–68) 53 (19–135) 38 (19–55) 105 (67–135)
ALP (U/L) [median (range)] (N: 40–120 U/L) N.D. 107
(42–251)
272 (84–571) 214 (84–430) 366 (232–571)
Bilirubin total (lmol/L) [median (range)]
(N:\ 17 lmol/L)
N.D. 8 (5–17) 11 (5–85) 6 (5–12) 35 (20–85)
Albumin (g/L) [median (range)] (N: 35–50 g/L) N.D. 42 (37–46) 40 (27–45) 43 (39–45) 33 (27–34)








Note that calculation of MRS for PBC employs different parameters, yielding values that do not allow direct comparison with MRS for PSC
HC healthy controls, PBC primary biliary cholangitis, PSC primary sclerosing cholangitis, MRS Mayo Risk Score, AST aspartate aminotrans-
ferase, ALP alkaline phosphatase, N.A. not applicable, N.D. not determined, N: normal range
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higher in the MRSintermediate-high than in the MRSlow sub-
group (Table 2; Suppl. Fig. 1A).
Serum bile salt composition at baseline is depicted in
Fig. 2. The mole fraction of primary conjugated bile salts was
higher in PSC than in PBC patients and HC (Fig. 2; Suppl.
Table 3). Moreover, the mole fraction of unconjugated
UDCA was elevated in PBC compared to PSC and HC, and
elevated in PSC compared to HC (Fig. 2; Suppl. Table 3).
Baseline elevation of serum bile salts in PSC was primarily
due to increased levels of primary conjugated bile salts.
Serum bile salt response to CDCA intake
Oral CDCA administration resulted in elevation of TBS in
all groups (ptime\ 0.001; Fig. 1a, Suppl. Fig. 1A). The
serum bile salt response to CDCA was different between
the three groups (ptime*group\ 0.001), with the response in
PSC patients deviating from that in HC and PBC patients
(Suppl. Table 1). While a transient elevation of TBS was
observed in HC and PBC patients, the response to CDCA
in PSC patients showed an enhanced and prolonged ele-
vation, which was predominantly due to a prolonged
response in the PSC MRSintermediate-high subgroup (Suppl.
Figure 1; Suppl. Table 1).
The time-to-peak (TTPTBS) for TBS was similar in HC
and PBC patients, but longer in PSC patients (Fig. 1;
Suppl. Table 2). In 9 out of 12 PSC patients and 2 out of 10
PBC patients, a second peak in the individual serum
response curves was observed between T = 5–8 h (data
not shown). These findings are reflected in a higher
AUCTBS0-8h in PSC patients in comparison with HC and
PBC patients (Suppl. Table 2). AUCTBS0-8h values were
similar in the MRS-based PSC subgroups (Suppl. Table 2).
For each of the subjects, serum bile salt pool compo-
sition was analyzed at the individual peak level, and peak
TBS level was calculated from the sum of individual bile
salt species (Fig. 3a). At the first peak, TBS levels were
higher in PSC and PBC patients than in HC (Fig. 3d),
whereas unconjugated CDCA was higher in PBC patients
than in HC (Fig. 3c). Peak mole fraction of conjugated
CDCA was highest in PSC (Fig. 3a). Moreover, MRSin-
termediate-high PSC patients had increased conjugated CDCA
levels compared to MRSlow PSC patients (Fig. 3b). No
differences were found between bile salt levels or com-
position at the time of the second peak, when comparing
PSC with PBC patients or MRSlow PSC patients with
MRSintermediate-high PSC patients (Fig. 3a, b, d).
FGF19 levels at baseline and serum response
after CDCA
Baseline serum FGF19 levels in both patient groups and
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caused a gradual increase in serum FGF19 levels in all
groups (ptime\ 0.001; Fig. 1b, Suppl. Fig. 1A). The serum
FGF19 response to CDCA was different between groups
(ptime*group = 0.018), with the response in PSC patients
deviating from that in HC (Suppl. Table 1). The first half of
the FGF19 response curves was similar in the three groups.
During the second half, the FGF19 response showed a
persistent elevation in PSC patients in contrast to a decline
in PBC patients and HC (Fig. 1b, Supp. Table 2).
C4 levels at baseline and serum response
after CDCA
In PSC patients, C4 levels at baseline were decreased
(Fig. 1c; Table 2). This is attributable to the MRSintermedi-
ate-high subgroup where C4 levels reached the lower limit of
quantification (i.e. 0.1 ng/mL). Levels of C4 in the MRSlow
subgroup were not different from those in HC or PBC
patients (Supp. Fig. 1C; Table 2).
The serum C4 response to oral CDCA administration
was significant in HC (p = 0.018), in PBC patients
(p\ 0.001) and in the MRSlow subgroup (p = 0.006), but
not in the MRSintermediate-high subgroup (p = 0.64). HC and
PBC patients showed a decrease in C4 levels in the second
half of the response curve, following the peak of FGF19
levels at 4–5 h (Fig. 1c; Suppl. Table 2). A similar
reduction of C4 levels preceded by elevation of serum
FGF19 was noted in the MRSlow subgroup (Suppl.
Fig. 1C). Serum C4 levels in the MRSintermediate-high PSC
subgroup were already low at baseline, and CDCA inges-
tion had no further effect (Suppl. Fig. 1C).
Discussion
In this study, we evaluated the gut–liver axis of FGF19-
mediated regulation of bile salt synthesis in PSC and PBC
patients by the oral administration of the natural FXR
agonist CDCA. In PBC patients and in healthy controls,
serum FGF19 levels peaked 4 h after oral CDCA and then
declined. In contrast, the serum FGF19 response curve in
PSC patients showed a prolonged response, with elevated
serum FGF19 levels up to 8 h after oral CDCA adminis-
tration. What could be the mechanism behind this pro-
longed FGF19 response in PSC patients?
CDCA is the most potent FXR agonist among the nat-
ural bile salts [4]. Passive or carrier-mediated absorption of
bile salts in the terminal ileum results in FXR activation
and FGF19 induction. FGF19 circulates from the ileum to
the liver where it suppresses bile salt synthesis [17]. While
FGF19 is not expressed in normal human hepatocytes,
under cholestatic conditions, human liver produces FGF19
[18]. Whether this occurs in hepatocytes or cholangiocytes
is not clear. A previous report showed a correlation
between serum and liver levels of FGF19 protein and
severity of cholestasis in PBC [19]. Although the regula-
tion of FGF19 in the liver is not entirely understood, it is
likely that FGF19 synthesis in the cholestatic liver is under
the control of FXR as it is in the ileum and can hence be
induced by CDCA.
Our study showed a prolonged serum FGF19 response in
PSC patients after oral administration of CDCA. The TBS
and FGF19 response curves showed that, in all groups,
TBS elevation preceded serum FGF19 elevation. In PSC
patients, persistent elevation of TBS was followed by
elevated FGF19 until 8 h after oral intake of CDCA, sug-
gesting that the decreased clearance of CDCA and other
bile salts in these patients results in prolonged FGF19
production. While FGF19 during the initial phase of the
response curve most likely derives from the terminal ileum
due to FXR activation by luminally absorbed CDCA, we
speculate that FGF19 in the second phase of the response
curve may originate from both the liver and ileum. Pro-
longed elevation of serum CDCA could stimulate FGF19
production in ileal enterocytes via basolateral diffusion of
unconjugated CDCA or via absorption and stimulation of
FXR in hepatocytes or cholangiocytes. The difference in
response between PSC and PBC patients may be related to
the degree of cholestasis, since PSC patients had higher
levels of ALP and TBS than PBC patients (Tables 1, 2;
Fig. 1a). However, we did not observe a correlation
between cholestatic parameters and FGF19 levels (data not
shown). In addition, FGF19 continued to rise until 8 h after
oral administration of CDCA in both MRSlow and chole-
static MRSintermediate-high PSC patients (Suppl. Fig. 1B). To
further study the influence of cholestasis on the serum
FGF19 response following an oral CDCA challenge, it
could be informative to evaluate this response in patients
with severe cholestasis, e.g., in patients with malignant bile
duct obstruction. We alternatively considered the possi-
bility that the difference in FGF19 response between PSC
and PBC patients may be disease-specific, rather than
related to differences in severity of cholestasis. In PSC,
intermediate and large bile ducts contain numerous stric-
tures. Proximal to these stenoses, the biliary pressure is
likely elevated, leading to the characteristic saccular
dilatations. Bile duct damage is different in PBC where
only the small intrahepatic bile duct(ule)s close to the site
of hepatocellular secretion are affected. Albeit difficult to
prove, it is possible that in PSC bile salts leak from these
injured bile ducts, especially from pre-stenotic segments
that may be under increased biliary pressure. This leakage
could be enhanced upon an increase in biliary pressure
after canalicular secretion of administered CDCA. As a
result, bile salts recirculating to the liver via such specu-
lated cholehepatic shunting could cause prolonged hepatic
136 Hepatol Int (2017) 11:132–140
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FXR activation and consequential hepatic FGF19 synthe-
sis. Moreover, FGF19 from bile could leak into the circu-
lation and directly contribute to elevated serum levels of
FGF19 after CDCA challenge in PSC [20]. The latter
scenario is less likely, as cholestasis and liver injury
markers were not affected by CDCA ingestion (Suppl.
Fig. 2).
Following a CDCA challenge, a larger fraction of
CDCA was conjugated in PSC patients at peak bile salt
level than in PBC patients. This especially occurred in the
MRSintermediate-high PSC subgroup (Fig. 3a, b). Also at
baseline, PSC patients showed increased primary conju-
gated bile salts, which largely accounted for elevated TBS
(Fig. 2). Since the liver is the only site where bile salt
conjugation occurs, conjugated bile salts in serum must
originate from the liver. Therefore, conjugated CDCA in
serum either originates from leaky bile ducts or from
reversed basolateral efflux from hepatocytes. In the
absence of a stimulus for gallbladder contraction, intestinal
reabsorption following enterohepatic circulation seems a
less likely explanation for serum appearance of conjugated
CDCA.
UDCA is a very weak FXR agonist [4]. In order to
prevent potential interference with CDCA effects, all par-
ticipants were requested to discontinue use of UDCA for
1 week. Longer discontinuation may have been preferable
for our study, but was not justified from an ethical and
medical point of view. UDCA was not discontinued by all
subjects. As a result, unconjugated UDCA remained ele-
vated in PSC and PBC patients (Fig. 2). However, there
was no correlation between baseline UDCA levels and
FGF19 or C4 levels (data not shown).
At baseline, PSC patients in the MRSintermediate-high
group had very low levels of C4 and normal levels of
FGF19 (Suppl. Fig. 1C). This could point to strongly
suppressed bile salt synthesis via FGF19-independent
pathways in progressive stages of the disease. Strongly
suppressed synthesis of (primary) bile salts can be expected
to result in a greater proportion of gut flora-derived sec-
ondary bile salts in the circulating pool. Yet, primary bile
a b
c
Fig. 1 Serum bile salt, fibroblast growth factor 19 and C4 response
curves following chenodeoxycholic acid (CDCA) administration.
Serum was sampled hourly until 8 h after CDCA intake in healthy
controls (HC, green symbols, n = 10), and patients with primary
biliary cholangitis (PBC, blue symbols, n = 10) and primary
sclerosing cholangitis (PSC, red symbols, n = 12). Data are expressed
as mean values and standard error of the mean. FGF19 fibroblast
growth factor 19, C4 7a-hydroxy-4-cholesten-3-one
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ab
Fig. 2 Serum bile salt composition at baseline. Serum bile salt
composition was determined in healthy controls (HC, n = 3), PBC
(n = 10) and PSC (n = 12) patients (a). Based on Mayo Risk Score
(b), PSC patients were subcategorized as low risk (n = 7, MRSlow) or
moderate to high risk (n = 5, MRSintermediate-high). Bile salt compo-
sition is represented as (un)conjugated primary, secondary bile salts
and UDCA. Data are expressed as mole fractions. The following
lowercase letters denote differences of statistical significance: a and
aa HC vs. PSC p\ 0.05 and p\ 0.005, respectively; b and bb PSC
vs. PBC p\ 0.05 and p\ 0.005, respectively; cc HC vs. PBC
p\ 0.005. HC healthy controls, PBC primary biliary cholangitis,




Fig. 3 Serum bile salt composition and peak levels following CDCA
administration. Bile salt composition was determined in samples from
healthy controls (HC, n = 3), PBC (n = 10) and PSC (n = 12)
patients at baseline and at time of peak(s) of total bile salts. Data are
expressed as mole fractions and categorized as (un)conjugated CDCA
and other bile salts (a). Based on Mayo Risk Score (b), PSC patients
were subcategorized as low (n = 7, MRSlow) or intermediate to high
risk (n = 5, MRSintermediate-high). Unconjugated CDCA absolute
concentration was measured at first total bile salt peak (c) in the
same (sub)groups used for (a) and (b). For the same groups, total bile
salt peak(s) are shown as absolute concentrations (d). For peak#2:
PBC (n = 2), PSCAll (n = 9), PSC MRSlow (n = 5) and PSC
MRSintermediate-high (n = 4). Data in (c) and (d) are expressed as
median and interquartile range. The following lowercase letters
denote differences of statistical significance: a and aa HC vs. PSC
p\ 0.05 and p\ 0.005, respectively; b and bb PSC vs. PBC
p\ 0.05 and p\ 0.005, respectively; c HC vs. PBC p\ 0.05; d and
dd PSClow vs. PSCmoderate-high p\ 0.05 and p\ 0.005, respectively.
HC healthy controls, PBC primary biliary cholangitis, PSC primary
sclerosing cholangitis, CDCA chenodeoxycholic acid
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salts comprise the main bile salt species in PSC. It will be
interesting to learn if CYP7A1-independent routes of bile
salt synthesis, which do not result in the formation of the
bile salt intermediate C4, are operating in PSC.
The findings of our study might be relevant for FXR
agonist-based therapy. A putative beneficial effect of FXR
agonists in PSC patients would be the suppression of bile
salt synthesis via FGF19 induction. Our data suggest that
PSC patients with intermediate–high MRS may not benefit
from this therapy, given the fact that bile salt synthesis, at
least via the classical pathway, appears to be already low.
However, FXR agonists may still have beneficial effects on
properties of the bile salt pool as well as gut barrier
function, exert anti-inflammatory action in intestine and
liver, and promote repair of cholestatic injury [21–26].
Our finding of prolonged FGF19 elevation in PSC
patients following CDCA intake may have additional
implications for FXR agonist-based therapy in this disease.
Obeticholic acid (OCA) is an approximately 100-fold more
potent FXR agonist than CDCA and is under current
investigation in a phase 2 trial in PSC patients [27, 28]. In
PBC patients, OCA at a dose of 10 mg was observed to
result in a ca. twofold elevation of serum FGF19 [29]. This
approximates the effect of CDCA in PBC patients in our
current study, as well as postprandial FGF19 changes in
healthy subjects [15, 30]. Based on our findings, prolonged
elevation of FGF19 may be anticipated in PSC patients
using OCA. Prolonged exposure to elevated FGF19 levels
may theoretically increase the risk of PSC patients for
developing cholangiocarcinoma and other malignancies, as
has been shown in mice [31].
There are some limitations to our study. As the physi-
ological stimulus of an oral fat load did not result in a
uniform serum FGF19 response (unpublished results), we
chose oral CDCA to induce intestinal FGF19 release. The
orally administered CDCA was not conjugated and is
expected to be taken up in part by the proximal small
intestine (which has little FXR and no FGF19 expression)
via passive diffusion [32]. Thus, oral CDCA ingestion does
not reflect normal physiology in which conjugated bile
salts are delivered to the terminal ileum by a meal-stimu-
lated gallbladder contraction. In addition, the PBC patients
had lower cholestatic parameters than the PSC patients, and
as such may be a suboptimal control group for cholestatic
disease. Moreover, to test our hypothesis of CDCA-in-
duced hepatic production of FGF19 in PSC, analysis of
liver biopsies taken before and after CDCA would be
needed. However, such invasive steps are ethically not
allowed.
Taken together, we demonstrate that PSC patients show
a prolonged FGF19 response after an oral dose of CDCA.
FXR-agonist therapy in PSC can cause prolonged exposure
to elevated levels of FGF19. Its previously reported hep-
atoproliferative properties warrant evaluation of the long-
term effects of elevated FGF19 levels in PSC patients.
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